ABOUT THE EVENT
Date: Thursday, July 23, 2026 9–10am PDT
Event Location: Virtual
In vitro assay evaluation is a critical component for T cell engager (TCE) drug discovery, providing essential insights into drug specificity, potency, and mechanism of actions (MOAs). A well-designed, stage-based assay strategy can help streamline project timelines, improve cost efficiency, and support lead candidate selection.
In this webinar, we will discuss how to tailor bioassays across different stages of TCE drug discovery, from high-throughput screening to lead optimization and comprehensive evaluation. Through real-world case studies, we will demonstrate how rational assay design, such as reporter gene assay of T cell activation, PBMC-based redirected killing, cytokine release profiling, serial killing, and bystander killing assays, and integrated assay workflow in stages, can support robust and efficient assessment during TCE discovery.
In this webinar, you will learn:
- Rapid HTP screening workflows to evaluate TCE formats and identify optimal pairings
- Fit-for-purpose in vitro assay panels to assess T cell activation, cytotoxicity, cytokine release, and potency for lead optimization
- Advanced assay design, such as serial tumor killing, to differentiate TCE leads and support translational decision-making
